XML 28 R42.htm IDEA: XBRL DOCUMENT v2.4.0.8
Basis of Presentation (Details Textual) (USD $)
 12 Months Ended 12 Months Ended 1 Months Ended 12 Months Ended 1 Months Ended 12 Months Ended 12 Months Ended
Dec. 31, 2013
segment
Dec. 31, 2012
Dec. 31, 2011
Apr. 30, 2013
program
Dec. 31, 2013
Stock Options
2002 Stock Incentive Plan
Dec. 31, 2013
Stock Options
Vest 1/8 on the six month anniversary of the date of grant
2002 Stock Incentive Plan
Dec. 31, 2013
Stock Options
Vest 1/48 each month for forty-two months
2002 Stock Incentive Plan
Dec. 31, 2013
Director
2002 Stock Incentive Plan
Dec. 31, 2013
Minimum
Dec. 31, 2013
Maximum
Dec. 31, 2013
Equipment
Minimum
Dec. 31, 2013
Equipment
Maximum
Dec. 31, 2013
CyDex
Dec. 31, 2012
CyDex
Dec. 31, 2011
CyDex
Jan. 31, 2011
CyDex
Jan. 31, 2012
CyDex
Guaranteed Payment
Jan. 31, 2010
Metabasis Therapeutics
right
Dec. 31, 2013
Metabasis Therapeutics
Dec. 31, 2012
Metabasis Therapeutics
Dec. 31, 2011
Metabasis Therapeutics
Apr. 30, 2013
Royalty Stream and Milestone Payments Purchase Agreement with Selexis
Dec. 31, 2013
Neurogen Corporation
Dec. 31, 2009
Neurogen Corporation
right
Dec. 31, 2013
Neurogen Corporation
VR1
Dec. 31, 2011
IPR&D MEDI-528
Dec. 31, 2011
IPR&D TRPV1
Dec. 31, 2013
Customer Concentration Risk
Accounts Receivable
customer
Dec. 31, 2013
Major Customer 1
Customer Concentration Risk
Accounts Receivable
Dec. 31, 2012
Major Customer 1
Customer Concentration Risk
Accounts Receivable
Basis of Presentation [Line Items]                                                            
Accumulated deficit $ (671,339,000) $ (682,759,000)                                                        
Working capital (4,100,000)                                                          
Period for which available resources are sufficient to satisfy company's anticipated operating and capital requirements 12 months                                                          
Common shares excluded from computation 800,000 1,100,000 1,000,000                                                      
Maturity period of cash and cash equivalents, maximum 3 months                                                          
Maturity period for short term investments, minimum 3 months                                                          
FDIC insured amount 250,000                                                          
Cash deposits 11,100,000                                                          
Concentration risk, number of customers                                                       2    
Concentration risk, percentage of accounts receivable                                                         75.00% 87.00%
Reserve for obsolete inventory 0 0                                                        
Accounts receivable outstanding considered past due after period, minimum 30 days                                                          
Accounts receivable outstanding considered past due after period, maximum 90 days                                                          
Allowance for doubtful accounts 0 0                                                        
Property and equipment, useful life                     3 years 10 years                                    
Depreciation expense 300,000 300,000 500,000                                                      
Definite lived intangibles, useful life 20 years                                                          
Amortization expense 2,400,000 2,400,000 2,300,000.0                                                      
Estimated amortization expense [Abstract]                                                            
Amortization Expense 2014 2,400,000                                                          
Amortization Expense 2015 2,400,000                                                          
Amortization Expense 2016 2,400,000                                                          
Amortization Expense 2017 2,400,000                                                          
Amortization Expense 2018 2,400,000                                                          
Intangible assets with definite lives                               47,469,000                            
Business combination, weighted-average amortizaiton period intangible assets                         20 years                                  
In-process research and development                               3,200,000                            
Goodwill 12,238,000 12,238,000                           11,538,000                            
Acquisition of intellectual property                                           3,600,000                
Gain (loss) on asset disposal 5,000 (17,000) (456,000)                   500,000 0                                
Impairment of IPR&D                                                   1,100,000 1,200,000      
Number of commercial license agreement programs       15                                                    
Purchase price                                           4,600,000                
Cash payment due on first anniversary of the closing                                           1,000,000                
Contingent value rights fair value                               17,600,000                            
Paid to CyDex shareholders 3,571,000 0 0                           4,300,000                          
Discounted to present value using a discount rate                               21.60%                            
Fair value of contingent liability                         9,300,000 10,900,000       9,100,000 4,200,000 0       3,200,000            
Contingent liability change in amount                         600,000 (3,400,000) 100,000       (4,200,000) 1,100,000 (1,100,000)   500,000   200,000          
Contingent liability, cash payment                         1,000,000 8,000,000 2,900,000                              
Number of contingent value rghts                                   4           4            
Number of contingent value rights per series of contingent value rights                                   1                        
Number of series of contingent value rights issued per share                                   4                        
Retirement of common stock held in treasury (in shares)                                   6 months                        
Retirement of treasury shares (in shares) 1,118,222                                                          
Product sales reporting period                 30 days 60 days                                        
Period allowed for return of products, minimum 30 days                                                          
Period allowed for return of products, maximum 90 days                                                          
Deferred revenue $ 100,000 $ 800,000                                                        
Share-based Compensation [Abstract]                                                            
Award vesting period           6 months 42 months 1 year                                            
Award vesting right percentage           12.50% 2.08%                                              
Award expiration period         10 years                                                  
Number of reportable segments 2